The challenge
Around 5% of adults globally are affected by metabolic dysfunction-associated steatohepatitis (MASH). Current treatment mainly consists of managing co-morbidities, lifestyle modification and ultimately liver transplantation.
Our client, a top-20 pharmaceutical company was one of the numerous companies with a pharmacologic treatment in development that directly targets MASH.
With the product in Ph2 clinical development, the client asked Inbeeo to develop an aspirational payer value narrative, to identify data gaps and inform future evidence generation.
The approach
Based on secondary research, Inbeeo drafted a high-level value narrative to capture the currently available information and aspirational value messages.
This approach allowed for integrating new data as they became available during clinical development and included branching points based on key scenarios.
Subsequently, the narrative was validated and refined by way of:
- A workshop with representatives from the Global Market Access, HEOR and Medical teams
- A further series of workshops with the defined key markets
The impact
Our inputs enabled the client to:
- Have a clear overview of scenarios and information gaps
- Understand the impact of scenarios on the value narrative and data needs
Decide on implications for the clinical development programme and further evidence generation
